5-aminosalicylate is not protective from neoplasia in ulcerative colitis

American Journal of Gastroenterology

Volumn 108, Issue 6, 2013, Pages 1015-

  Bessissow, Talat ^a   Bisschops, Raf ^a   Ferrante, M ^a   Baert, F ^b   Van Assche, Gert ^a   Rutgeerts, Paul ^a   Vermeire, Severine ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b McGill University Health Center ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

CANCER PREVENTION; CHROMOENDOSCOPY; COLORECTAL CARCINOMA; COLORECTAL TUMOR; CONTROLLED STUDY; DISEASE DURATION; DYSPLASIA; ENDOSCOPIC SURGERY; HUMAN; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ULCERATIVE COLITIS;

COLORECTAL NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE;

EID: 84878904696     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.121     Document Type: Letter

References (5)

1. Nguyen GC, Gulamhusein A, Bernstein CN. 5-Aminosalicylic acid is not protective against colorectal cancer in infl ammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol 2012 ; 107 : 1298-304.
2. Bernstein CN, Nugent Z, Blanchard JF. 5-Aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 2011 ; 106 : 731-6.
3. Velayos FST, Jonathan P, Walsh JM et al. Eff ect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta analysis of observational studies. Am J Gastroenterol 2005 ; 100 : 1345-53. (Pubitemid 40904360)
4. Eaden J, Abrams K, Ekbom A et al. Colo rectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Th er 2000 ; 14 : 145-53. (Pubitemid 30088290)
5. Jess T, Loft us Jr EV, Velayos FS et al. Risk factors for colorectal neoplasia in infl ammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007 ; 102 : 829-36. (Pubitemid 46496613)